Stockscreener 앱 받기
1.01
10.62%
-0.12
전일 마감가:
$1.13
열려 있는:
$1.135
하루 거래량:
36,715
Relative Volume:
0.31
시가총액:
$12.42M
수익:
$31.56M
순이익/손실:
$-46.89M
주가수익비율:
-0.333
EPS:
-3.0329
순현금흐름:
$-26.70M
1주 성능:
-15.83%
1개월 성능:
-38.41%
6개월 성능:
-45.99%
1년 성능:
-75.60%
1일 변동 폭
$1.01
$1.17
1주일 범위
$1.01
$1.25
52주 변동 폭
$1.01
$4.18
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
CASI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
1.01 | 23.22M | 31.56M | -46.89M | -26.70M | -3.0329 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 개시 | Mizuho | Buy |
| 2020-10-23 | 개시 | Oppenheimer | Outperform |
| 2016-09-22 | 개시 | Maxim Group | Buy |
| 2015-10-29 | 재개 | H.C. Wainwright | Buy |
| 2015-06-23 | 개시 | H.C. Wainwright | Buy |
모두보기
Casi Pharmaceuticals Inc 주식(CASI)의 최신 뉴스
Lacklustre Performance Is Driving CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) 27% Price Drop - simplywall.st
CASI Pharmaceuticals Inc. (CASI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Casi Pharmaceuticals appoints James Huang as non-executive chairman - MSN
How resilient is CASI Pharmaceuticals Inc. stock in market downturns2025 Key Lessons & Long-Term Capital Growth Strategies - newser.com
How CASI Pharmaceuticals Inc. stock performs in weak economyGap Up & Daily Growth Stock Tips - newser.com
How to read the order book for CASI Pharmaceuticals Inc.2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
Is CASI Pharmaceuticals Inc. stock gaining market shareJuly 2025 Trends & Growth Oriented Trade Recommendations - newser.com
CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman - MSN
Is CASI Pharmaceuticals Inc. stock a top momentum playMarket Performance Summary & Weekly High Potential Alerts - newser.com
[6-K] CASI Pharmaceuticals, Inc. Current Report (Foreign Issuer) | CASI SEC FilingForm 6-K - Stock Titan
CASI Pharmaceuticals Announces Changes in Board Governance - Eagle-Tribune
CASI Pharmaceuticals (NASDAQ: CASI) appoints James Huang Non-Executive Chairman - Stock Titan
What MACD and RSI say about CASI Pharmaceuticals Inc.2025 Macro Impact & Fast Entry Momentum Alerts - newser.com
Smart tools for monitoring CASI Pharmaceuticals Inc.’s price actionTrade Analysis Summary & Safe Swing Trade Setups - newser.com
Is CASI Pharmaceuticals Inc. stock attractive for retirement portfoliosTrade Performance Summary & Consistent Profit Focused Trading Strategies - newser.com
Can CASI Pharmaceuticals Inc. stock resist sector downturnsBuy Signal & Expert Approved Momentum Trade Ideas - newser.com
Will CASI Pharmaceuticals Inc. stock attract more institutional investorsChart Signals & Capital Protection Trade Alerts - newser.com
CASI Pharmaceuticals Stumbles On Revenue Drop And Nasdaq Challenge - Finimize
CASI Pharmaceuticals Reports Q3 2025 Results Amid Nasdaq Delisting Appeal - MSN
Casi Pharmaceuticals Q3 revenue drops 60%, net loss widens - MarketScreener
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens - TradingView
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results - ACCESS Newswire
CASI Pharmaceuticals (NASDAQ: CASI) reports third-quarter revenue $3.1M; net loss $10.9M - Stock Titan
CASI Pharmaceuticals (CASI) Projected to Post Quarterly Earnings on Friday - Defense World
CASI Pharmaceuticals, Inc. (CASI) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
CASI Pharmaceuticals Appeals Nasdaq Delisting Determination - MSN
CASI Pharmaceuticals faces Nasdaq delisting over market value requirement By Investing.com - Investing.com Nigeria
Casi Pharmaceuticals Inc (CASI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.76%
2.16%
자본화:
|
볼륨(24시간):